Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. - Wikidata - awgldk - TriplyDB

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

http://www.wikidata.org/entity/Q34339890

about

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations Chemotherapy for advanced non-small cell lung cancer in the elderly population Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer Immunotherapy for lung cancer Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes Afatinib for the treatment of metastatic non-small cell lung cancer From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Lung cancer in Brazil: epidemiology and treatment challenges.Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?Strategies for modern biomarker and drug development in oncology.Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.Molecular pathways and therapeutic targets in lung cancer Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma Tongue carcinoma infrequently harbor common actionable genetic alterations Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.

P2860

Q21132357-5D50CD57-430E-4BDD-A013-2AB9DA3B9C83 Q24186466-06E9F912-57D0-4444-96B0-26CBDFDA6EFA Q24564024-0033061E-7170-47B6-910F-D44B8A328AB0 Q26471909-A1BBD82C-8160-4D95-AE7D-E649F6640804 Q26751254-EA54476C-F10C-441E-98B4-866BD3EE9874 Q26771116-C65CA912-2C9E-49EC-A342-2E75E1C0B3AE Q26784298-B644463E-FC15-4386-868F-BB4F3FCF4254 Q26798882-764DE28B-7E87-456A-A215-5BFA7E7CDB0E Q26825636-9AF1C876-CD12-4C6E-937E-C2EBCDC5515D Q27004790-76D661C2-12AC-49B4-B8BD-C86F1DE59EDF Q27853317-6ACC44D4-B662-4AC7-8C46-4699FF64AECB Q28076646-3D4FA8A0-C418-4939-BFFE-EE8A34280CC5 Q28081319-FF83B019-9867-4033-9769-937E5C0D1687 Q28082181-DFB1FACD-BAD6-4693-8370-287F1078B900 Q28385559-01C56DE6-BA70-4518-8FDB-5868203B6051 Q30234436-001DEE38-1B92-4645-A4A5-F7ACA36093AC Q30235908-651DF8BE-83F9-4B78-8F56-781297C30558 Q30316339-4E40588C-99DC-4ADC-BC40-BC9051515AA9 Q30590270-9FBC3557-C020-466C-AAE8-597CD544B37E Q33416457-D0DF8EBE-EF5B-4C77-AF2D-4700D3FF343E Q33423782-AC6C1AB3-15D8-4E2E-8E4B-6178CECE47D9 Q33433360-82DC42D1-745B-4508-A190-11D1C5415B70 Q33648808-3504724F-A4F8-417C-9182-57A7576E8B43 Q33662730-B974F422-CBD6-42DD-870F-87CC170BCF12 Q33688872-FA5A4F4E-EFF6-49A2-8A43-DFCA79941E33 Q33710146-2428B519-135C-42B7-B7B7-98BDCE079808 Q33779727-EB3B4F50-E501-4605-9441-00ABDDEF8ABF Q33798819-129E6C44-B094-4985-A7B9-7266D945200A Q33878770-AE0A3986-FD83-49F4-95A7-BD4F691454D4 Q34031229-F9A170A5-0AB9-4D78-8F5B-F633FF7516E9 Q34051516-68E371AE-BB02-45D7-96FE-084A34343B33 Q34172448-4BE2DC7B-E917-41D2-831A-2FD4ACD513C2 Q34256064-C1AF0631-3E08-40BA-9492-8BD1F1DE43B1 Q34258399-5A7A6E8A-06F8-4C93-A045-698D4B1B8BFB Q34354339-028D5581-204E-4D4F-B856-5758C4C77C2B Q34452186-5D3D739D-5EAB-4884-80E2-2F29FA99F0E5 Q34538361-2A30CD60-CAC6-420F-8997-1C7C9C430338 Q34571689-389CEC32-B7B5-41F3-9E8F-053E857FB946 Q34663877-56F6BFD2-AC11-429E-B951-D3A57FCA159E Q34809526-280AD0FB-8848-411F-9B77-F99A7C4FA5E0

P2860

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

http://www.wikidata.org/entity/Q34339890

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@ast

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@en

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@nl

type

label

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@ast

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@en

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@nl

prefLabel

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@ast

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@en

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@nl

P1433

Q34339890-1329DFAD-0149-4BC9-BF8B-B40A57A0C261

P1476

Q34339890-3397048F-B59B-4E12-A9A2-0F5D7F5B6B0C

P2093

Q34339890-2BC731DA-B335-4827-98E6-2CB5230DE912

Q34339890-48E2BB5E-A31E-4B86-9916-C2192C79EB47

Q34339890-6B77B4F7-38C3-49B9-9AC0-37C2F0C16B68

Q34339890-6E9E2BED-E2EE-4447-90DA-1D9BE16B2A0E

Q34339890-9F0CD58C-CA9D-495C-9AFE-322DE49750FC

Q34339890-ACA0A7CF-97BC-47D1-86A7-032E922E9939

Q34339890-B54614FD-1FA4-42B7-8841-E985300C535F

Q34339890-BD342A4F-F2B8-40C7-BBB6-C3697FE6DC4E

Q34339890-E64FAC5B-3932-4D71-916A-0ACE186F9D91

Q34339890-EB781E26-C9F7-4C4C-BCEF-1DBA93D686D6

P2860

Q34339890-05A59F9C-46F1-4525-BA37-345DB733635C

Q34339890-07DCF690-7F2A-4E98-BDF6-770DC6E623A6

Q34339890-0C7527B9-6E97-416A-B0F6-276EAA405E72

Q34339890-0D9F3097-0DF0-4A4D-9491-265FA2922C08

Q34339890-0F9ABB8A-C536-4C9E-814C-747F452C9687

Q34339890-10A557FC-B02B-4088-8163-44D5D053C1B4

Q34339890-16F02235-D5BC-4CBD-9E04-9239BF479568

Q34339890-1B9E7842-4215-43FD-91A9-E8207D1CFBE2

Q34339890-1BC5F490-68F6-4201-B4B6-45CE38A027E4

Q34339890-1D71B942-9CA6-4616-9A03-99CD66AB8A08

P304

Q34339890-C8AEC534-B1C9-40CC-93F5-AED81E74D762

P31

Q34339890-D0CA00B8-EBEB-4BA7-874C-18578BB1D4DB

Q34339890-c63be4bd-5f4c-4ba0-8d17-b2124ad7f985

P356

Q34339890-0063AD16-A5D9-406D-B81E-6146D6AD82B6

P407

Q34339890-B81BB4A0-B7E0-48C0-A956-14E833C552AE

P433

Q34339890-E637E0FC-FC46-4A47-B646-5F9C25A09DD1

P478

Q34339890-8AACC379-B822-49B8-83E5-4F4F58EAB569

P50

Q34339890-450EA11D-7712-4A8C-9DD3-61527BEF6BE9

Q34339890-9632B030-36C5-420E-AA4C-4181F27C3106

Q34339890-99F02EC6-D50E-4DD5-A743-65A9F81C2132

Q34339890-A8BC6C75-CCA9-484A-AD49-EEB4DDEB1B5A

Q34339890-B5FEA39E-9004-4AB1-8D70-B1DDB7D4221B

P577

Q34339890-D4E1472E-FBA2-4730-A040-87C3F3E61BEF

P5875

Q34339890-A81A6DF0-8B92-4476-95E6-44609130F2CF

P698

Q34339890-C0A6C286-0BD8-44E0-BED3-60160566AD13

P921

Q34339890-9E5D5152-63BF-4356-BBD7-D1DAB59B589E

P356

P1433

Journal of the National Cancer Institute

P1476

Impact of EGFR inhibitor in no ...... all survival: a meta-analysis.

@en

P2093

Adel Zaatar

http://www.w3.org/2001/XMLSchema#string

Akira Inoue

http://www.w3.org/2001/XMLSchema#string

Chun-Ming Tsai

http://www.w3.org/2001/XMLSchema#string

Da Tong Chu

http://www.w3.org/2001/XMLSchema#string

Eng Huat Tan

http://www.w3.org/2001/XMLSchema#string

Jemela Anne Osorio Sanchez

http://www.w3.org/2001/XMLSchema#string

Joseph Siu Kie Au

http://www.w3.org/2001/XMLSchema#string

Richard J Gralla

http://www.w3.org/2001/XMLSchema#string

Sumitra Thongprasert

http://www.w3.org/2001/XMLSchema#string

Val Gebski

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

P304

595-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT072

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

James Chih-Hsin Yang

James Chung-Man Ho

P577

2013-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236223752

http://www.w3.org/2001/XMLSchema#string

P698

23594426

http://www.w3.org/2001/XMLSchema#string

P921